Joseph A. Tyndall - 24 Jun 2026 Form 4 Insider Report for Axogen, Inc. (AXGN)

Reporting relationship: Director
Issuer ticker: AXGN
Reported as of: 24 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Jun 2026, 16:52:43 UTC
Prior SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Marc Began as attorney-in-fact for Joseph A. Tyndall

Key filing fact

Joseph A. Tyndall filed Form 4 for Axogen, Inc. (AXGN) on 26 Jun 2026.

Key facts

This page summarizes Joseph A. Tyndall's Form 4 filing for Axogen, Inc. (AXGN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 Jun 2026, 16:52.

Change

Previous filing in this sequence was filed on 23 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001955281 Primary reporting owner

TYNDALL JOSEPH A.

Relationship: Director
Address: C/O AXOGEN, INC. 13631 PROGRESS BLVD.,, SUITE 400, ALACHUA
Signature: /s/ Marc Began as attorney-in-fact for Joseph A. Tyndall
Signature date: 26 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AXGN transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +4,392
Change %
Price: $0.000000^*
Shares after: 4,392
Date: 24 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,392
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

Footnote F2

Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.